Market Overview

UPDATE: Jefferies Raises PT to $23 on Solazyme Post Q3 Beat

Related SZYM
Mid-Afternoon Market Update: Celator Pharmaceuticals Surges On Phase 3 Trial Results For Vyxeos; Constellium Shares Slide
Mid-Day Market Update: Inogen Jumps On Upbeat Results; Foresight Energy Shares Decline

Jefferies reiterated its Buy rating on Solazyme (NASDAQ: SZYM) and raised its price target from $22 to $23.

Jefferies commented, "Q3 was $0.06 better than consensus ($0.05 above our forecast). The current projects remain on track, but the real milestones were Bunge expanding its plans even before Moema starts, a new agreement with ADM, another tailored food oil and a test marketing program for Soladiesel. The focus now shifts to winning downstream partnerships."

Solazyme closed at $7.09 on Wednesday.

Latest Ratings for SZYM

Mar 2016Goldman SachsMaintainsNeutral
Nov 2014Morgan StanleyDowngradesOverweightEqual-Weight
Nov 2014Credit SuisseMaintainsNeutral

View More Analyst Ratings for SZYM
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (SZYM)

View Comments and Join the Discussion!

Partner Center